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Summaty, discussion and perspectives
Summary
This thesis describes the selective deliverl of dexamethasone to actir-ated er-rclrthelial cells.
using E-selectin as a target molecule. r\ctir.atcd endotl'reiial cells plar- an important rolc in
the pathophysiologl' of chronic inflammatory cliseases ancl are therefcrre considered
valuable targets for pharmacokrgical inten'ention. Dexarnetl-rasone is a corticosteroidal anti-
inflammatorv drug with a wide spectrum of pharmacological effccts and is therapeuticalll'
used in a variety of chronic inflammatory diseases. Howcver, its use is associated rvith
serious side effects such as osteoporosis and diabetes, thus hampering long-trrm svstemic
applicarion. Cell selective deLiverv of dexamethasone to activated endothelial ceils might
circumvent these problems.
l,ittle is known about targeting drugs to actir.ated enclothelial cells in ger-reral and
conicosteroids in particular. This thesis describes thc de',.elopment and characterization of
drug targeting preparations that contain dexamethasone as a rnodei anti-inflarnmatorv drug
and anti-E-selectin antibodies as a horning device. An immunoconjugate as rvell as an
immunoliposomal formulation were produced and investigated. Studies includecl analvses
of in yitro binding and internalization of developed preparat"ions into activated enc'lothelium,
as well as in uit'o accumulation in int]amed tissue. Several murine models of intlammation
have furthermore been investigated regarding fi-selectin mRNA and pr()tein explession.
These models mav be used to examine therapeutic effects of der-eloped drug targeting
preparations.
In chapter 1 the aim of the thesis is presentcd. Chapter 2 revieu's targetir.rg oi drugs to
vascular endothelium in inflamed tissue. The pathophysiology of inflammaticxr is de scribed
and possible target epitopes and targeting devices are summarized. Drugs possiblv




uiuo techntques to studv endothelial ce1l activation and intlammation. Finallv, general
considerarior-rs and practical clirections are presented for targcting acti\-atecl errdothelial cells
as a new approach for the tre atment of chronic inflammatory disorders.
Chapter 3 and 4 describe the development and chracterrzauc'tn of dexamethasone-anti [i-
sele ctin (dexa-Abr"a) immunoconjugates. In chapter 3, binding and internalization of dexa
Abr;."r into activated endothelial cells was qualitativel,v studied using a varietv of techniques.
These included immunol-ristochemistrr', confocal laser scanning microscopv and immuno-
transmission electron microscop,v, shcrwing that the conjugate selectjvelv bound to and rvas
intemalized into activated endothelial cells. Furthermore, the conjugate was subsequentlv
intracellularlr' routed to multi-vesicular borlies, ryhich are lvsosomal compartments of the
cell, Degradation of intracellularlv delivered dexn Abn."r resulted in release of
pharmacologicallv actjve dexarnethasone, as show-n using a GRF, (glucocorticoid responsive
element) drir-en reporter assay and Northem blot analysis of IL 8 mRNA ler-els.
In chapter 4, radioactivelv labeled dexa-Ab1..r u'as used to quafltitativell determine the
kinetics of binding ancl internalization oi dexa-Ab1,.r into activatetl endothelial cells. This
was compared to the cellular uptake of unconjugated dexamcthasone, which can reaclill.
pass cellular membrancs without the need tbr a (saturablc) carrier system such as li-selectin.
It was shorvfl that, upon incr,rbation with coflcentrations unconjugated dexamethasone
exceeding 3 pNl, higher intracellular ler.els of the cirug rvere echieved cor-npared tcr
dexa-Ab1,.r. Hou.evet, the conjugate has the advantage of selectir.el_v delivering
dexamethasone into activated endothelial cells ar-rd not into resting endothelial cells. l'his
characteristic will avoid dexamcthasone-associated side effects in other cell n'pes of the
bodl'. Furthermore, the amount that can be intraccllularll' delivered using dexa-Abr.."r is
sufficient fbr pharmacological effects of dexamethasone in uilra, as was demonstrated in
chapter 3 by inhibition of IL 8 mRNA expression bl' activated endothelial ceils.
In chapter 5, dexa Ab1..r immunocolriugates were compared with Abn""rimmuno-
liposomes cofltainiflg dexamethasone phosphate rvith regard to binding and internalization
in t'itro. It was shown that thc immunoconjugates were internalzed b1. actir.ated endothelial
cells to a larger extent than the immunolipc)somes. However, due to their hieh drug loading
capaci6', immunoliposomes rvill in theon. be able to deliver more dexarnethasone in the
cel ls.
The bod,v distribution of both drug targeting preparations was studied in a murine delayed
qpc hlpersensitivity model, irr wl.rich E-selectin is expressed b1' activated cndothelial cells in
inflamed skin. Both dexa-Abp."r and Abp."r-immunolipomes were cletected in endothelial
ceils in inflamed DTH skin, nlthor-rgh Ab,,,1,,,"1-liposomes coukl also be clearly visual.ized in
the unaffected skin. The reason for the latter obserwation remains obscure. In addition,
dexa-Abr:."1 could not be detected in organs iike brain, iung, kidnev and liver, whereas
Liposomes rvere detected in non-parenchymal cells of the liver and the splee n, represendng
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cells of the reticulo-endothelal s].stem. This accumulation in flon target cells mav lead to
the emersence of side-e ffects of the immunoliposomal clrug targe ting preprration, although
the balance between effects and side-et-fects mav still be favorable compared to untargeted
dexamethasone. Future studie s investigating anti-inflammatorv effects in approprirte
models of inflamrnatjon should reveal the therapeutic possibilties of both t,vpes of drug
targetinll systems for the treatment of chronic inflammatorv clisorders.
In chapter 5 the delaved tl'p. hvpersensitir'ih' model rvas used to determine homing
capacities of devcloped dmg targctinlJ preparations. Hon'eveL, the delayed tl'pe
hr,persensitivifi model is a transient model, u,-hich means that the clisease resolves bv itself
in a short period of time. Using E-selectin directed clug targetine strategies, the targered
drug will be deiiveted at a stage in the int'lammatory process rvhen interference u.ith
endothelial cell activation mav be too l,;rte for therapeutic effects. Hence. it is anticipatecl
that a chronic model oi inflammation is necessarl' to studv therapeutic effects of the
developed clrug{ targeting preparations. Therefore, in chapter 6, several murine models of
inflammation were investigatecl regJarding I,i-selectin expression, both on mRNA lnd
protein level. Whereas rnRNA levels are indicative of gene transcriptional activitv,
transmembrane expression of E selectin bt the actir.atecl endothelial cells is a prerequisire
for specific homins of E-selectin directcd dru€l targe ti,rg preparations.
\(/e showed that in all models [i-selectin mRNA could be dctected. In contrast, using three
different antiboclics that recosnizc different epitcipes of thc E, selectin molecule , E-selectin
protein expression could not alway's bc visualized. This stresses the necd to detcrmine E-
selectin expression at the protcin level ar-rd not at the mRN;\ level on1y, before choosing a
model for studl-ing therapeutic effects of E selectir.r directed drug targeting prcparatir,ns.
These obsen'ations also en-rphasize the importance of the choice of the antibod,v to be uscd
as a homing del'ice in relatjon to the animal model under stud.v. In addition, u,hen using
C5lBl/6 mice, the particular tissue affectecl was a detenninant in whether E-selectin
protein could be detected or not (skin versus aorta). This suggests spatiotemporal and/or
pathophlrsiel6gical determined differences in expression of different splice-variants of E
selectin bv micro and macrovasculature, as has been described for rats and humans.
Together, the results presented in this thcsis demonstrate the potential of targeting
dexamethasone into activated endothelal cells via E-selectin. Using an immunoconjugate,
dexamethasone can be intracellulady delivered in t,if:. Immunoliposomes, whicl-r have a
high dexamethasone loading capaciq., are also selectivelv internalized by activated
endotheLial ce1ls. Both these dru.q-targeting constructs accumulated in acrir.ated endotheliai
cells in inflamed sktn in uiua, although the immunoconjugate showed more selective
targeting tl-ran the immunoliposomes. Future studies using murine models of chronic
int1ammation will have to eluciclate the therapeutic perspectives oi drug-t:rrgeung strxrcgies












In gencrtl, drug-t';rrgeting constructs consist of a drug, a homing device and a carrier
molecule. The carrier molecule can also have intrinsic homing capacities, as is the curse in
c.g. immunoconjugatcs *'here the clrug is directiv coupled to an antibody. In the here-
presentecl thesis research, dexamethasofle \vas used as a model anti-iflflammatory dtug in
the protein based drug-targedng constructs. In addition to its broad anti inflammatory
efiecrs, clexamethas<-rr-rc u'as chosen as a model drug because of the availabilitl- of an anti-
dexamethasone antibodr, and afl HPI-C analt'sis svstem to characterize the
immunoconjugatcs. Both free and con jugatecl dexamethasone demonstrated
pharnracological et-tects in rctivatecl endothelial cells z)r t'llro, as demonstrurted by the partial
inhibition of IL8 rnRNA expression. Effects of (conjugated) dexamethasone on activated
endothelial cells rvcle investigated in more detail using a cDNA expression array, showing
inhibitorv effects on expression of tor instancc TGFp, IFNp and CD40I-, in addition to
IL-8 inhibition (S.A. Asgeirsd6ttir et al, submitted). Hou,.ever, it is not fullv understood
rvhethcr these phan-r-racological effects also occur in ilrt and, if so, to what extent they
contribute to thc anti-int-hmmatorv effects of dexamethasone. It has been described in
Literarure that glucocorticoid treatment in patients u'ith inflammaton bowel disease results
irr uprcqulation of IrB (inhibitor of NFrB) in er.rtlotheLial cells [1]. Vhether this is a direct
conseque nce of dexamethasone interaction u'ith e nclothelial cells or ^fi indirect
consequcnce of inhibition of leukocvte activation remains unclear, also because endothelial
cclls from rlifferent solrrces rcspond clifferentlr to glucocorticoicls in uitrt, rvith regard to
incrcasecl IKB expression 12,31. ()nIt' in riuo l-nzrlr-sis o[ therapcutic effects of targeted of
clexamethasone in chronic inflammaton' diseasc will reveal whether this srategl. will result
in re cltrction of lcukocvte rccruitment ancl hencc improvement of the diseases state.
Cellular adhesion molecules are considered critical mediators in the recruitment of
leukocvtes into inf'lamed tissue. Pharmacological agents that u"ould prevent the induced
expression of one or more of the cell adhesion molecules on the endotheliun-r likelv
attcnuate this inflammator\. responses. Hence much effort has been put into the
development of spccific inhibitors of these r.nolecules, such as for instance ICAN{-I
antisensc moleculcs, v'hich shou'ed profound anti-inflammatorr, effects in laboratory
animals [4]. The obsen'ation that in a placcbo controiled trial in patients with active
Crohn's t l iscasc anti- ICA\l 1 antisense trcatment results s-ere disappoint ing is possibly due
to redunclant leukocvte recruitment mechanisms [5].
Despite the pharmacological effects on the above described genes, dexamethasone dicl not
reduce adhesion rnolecule expression in actir-ated enclothelial cells zri vilrv, in contrast to
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Figure 7L:fi:ct.r oJ inltibitars af si.gtta/ tnn.rdaction on LILtI'E,C IC.,llt't'7 (nhite barc) and l,'(^,4\t-1
(b/ackbarc). HUITC utre treated.for 24 b tvit/t 1()0 ng/ nl 'tilif-a huthn'n'itlL 10 lt'\4
dexanetha.rane Q)), panlLenolide (P), .11120Jr80 (S) ar n'oimannin (IL:). Ce//.r a,erc han'e.rted, staintd
f-or (CAA,I I ar L'(,,A\I-/ expnssion aud and!,"1ed asiry.fhut c/t0/t/411'. Bar.r rupnsent nean t .rd
(n=)). (Ttgure repradaced lron .f ..1. ,l.tgeindt)tttr tr a/, subnilted)
From these data it can be concluded that, u,'hen aiming at dc,l'nregulation of Cr\trI
expressior.r, compounc'ls that inhibit NFrB (parthcnolide), p38 N{APkinase (S132t)3580) or
PI3-kinase (wortmannin) are suitable candiclates for sele ctir.c targe ting to actjvatcci
endothel ium. Recause these compounds inhibit  both ICAN{-I ancl VCANI-I,  ns rvel l  as
cvtokines like IL-(r and IL-U (data not shown), the problem of redr"rnclant leukocvte
recruitment mcchanisms rvill likelv be reduced.
It must be kcpt in mind, though. that cancliclzrte clrues must mcet certain rccluircments
regarding their chemical structure and hydrophilicitv. Thc chemical structlrte needs to
contain functional groups that can be used for inimunoconjugatc svnthesis, such as a
h_vdrcrxt'l-, amine- or carboxyl-grciup. Ilrom the perspectivc r,f thc signal transduction
inhibitors c'lescribed above, only rvortrnannin is suitable firr covalent conpling to an
antibodv [6]. Palthenolicle and 58203580 w<-ruld not be suitable because thel'lack proper
functional groups. Hol'evet, drugs derivecl from combinatorial chemistrv procedures
usualll bebng to a familv of structunlh' related cermpouncls, u'hich have the same
pharmacodvnamic profile but slighth' di[ferent molecular structures. This is tbr instance tl.re
case for the p38 N{APkinase inhibitor 58203580, rvhich is structurallv rclatecl to the






contains a hvdroxvl group in its strucrure. Covalent attachment of drugs to protein carriers
will allow intracellular release of the drug and hence local pharmacological effects, as
demonstrated b,v the inhibition of II- 8 mRNA expression by conjugated dexamethasone.
The hldropfiil-icit1' ef these compounds may be important in the development of liposomal
drug formulations. In theory, both h,vdrophilic and hvdrophobic compounds can be
included in Liposomes, bv incorporation in the aqeous inner space or in the liposomal
membrane, respectivelv. However, spofltaneous release of the compound from the
liposomes remains a possibilitl., and will alwa,vs have to be determined with regard to each
liposome preparation. Also in this case, the existence of structurallv related compounds
with slightll' different ph,vsicochemical properties mav be helpful in the development of
stable, liposome based, drug targeting preparations. In this thesis the pharmacological
effects of dexamethasone-phosphate entrapped in immunoliposomes have not been
investigated. It is therefore not known whether incorporated dexamethasone will be
intracellularlv released, after internaLizatton of the liposomes in the activated endothelial
cells. However, the toxiciq' of doxorubicin-loaded Liposomes to activated endothelial cells in
ritra clescdbed in literature [7], suggests proper degradation of the liposomes, and
subsecluent release and pharmacological effects of targeted drug. Nonetheless, the efficacv
of these intracellular processes will also be dependent on the abiliw of the drug to Pass
cellular membranes, and may thus be different for different compounds.
In general, newlv developed therapeutic modalities may have favorable pharmacological
properties in uitro as well as in uiua, but their pharmacokinetic profiles or side-effects ma,v
impede their further development into clinicallv useful compounds. This is especially the
case for therapeutic proteins, gene expression regulating medicines (e.g. antisense) and gene
therapv. In these cases, drug targeting mav prove to be a useful tool to overcome these
difficulties [8].
In this research project the drug-targeting constructs contained an anti-E-selectin antibodv
(Abn.") as a homing device, which also functioned as the carrier molecule in dre case of the
dexa-Abr,.a conjugates. The used mutine anti human E-selectin antibodl'recognizes the binding
domain for carbohydrate ligands. Hence, the antibody will compete with leukocl,tes for E-
selectin binding, thereby reducing the number of leukocytes that can be recruited. This ma,v
contribute to the anti-inflammatorv effects of the drug targeting preparations. The use of this
particular antibodl., in both dexa-Abna and Abn,.rlposomes, thus represents a dual targeting
sffategv in which respectir.ely the carrier molecule and the homing device, in addition to the
delivered drug, can exert a therapeutic effect. The used antibody is however not suited for future
clinical use, since murine antibodies have short circulating half-Lives in humans and induce
human anti mouse antibod.v responses. Fortunateil,, advanced molecular biologrcal techniques
have crcated dre opportunitiy to produce chimeric or humanized antibodies that, when clinicaliy
appLiecl, har,-e a reduced immunogenicity while maintaining their ll-selectin blocking function.
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Instead of antiboclies, peptides recr>gnizing E selectin can be used as a homing clevice to
avoid human anti-mouse antibod.v responses. -fhe advantage of some peptjdes described in
literature is furthermore the recoqnition of humrn, rar and nrurinc []-sclectin molecuics
[9, 10]. This is in contrast to monoclonal anti-E-selectin antibodies, which lack species
cross teacti\.it),. Initial studies in 6ur laboratory in which ll-selectirr recosniziqg peptides
u'ere coupled to protein backbones showed binding of the resulting constructs to an
immobilizecl IgG E-selectin fusion protein. However, using immunohistochemistrr,, the
conjugates rvere shou'n to b.ind to both resrir-rg and activated endotheLial cells, indicating
loss of E-selectin speciflcitv (RJ. Iiok, unpublished obsenations). Based on this result, u'e
decided to alwavs analvse birrcling characteristics of developed drug targeting c(rnstrLrcts fr)
activated endothelial cells in culture instead of studving only binding to isolated E selectin.
Furthermore, constructs should be tested ifl animal models as soon as possible fbr homing
capacity to the chosen target molecule . C)nlr, th.is parameter rvill indicate the pote ntial of the
der-eloped drug targeting construct to tarset activated endotheLial cells in inflamed tissue.
In contrast to targeting relativelv large or55ans like liver, kidnev or tumors, the targeting of
drugs to activatecl vascular endothelium is difhcult to cluantify u'ith the use of radiolabelecl
constructs. This is especiallv troublesome because endothelial cells constirute onlv a small
percentage of the total cell population in a part-rcular tissue. The accumulated lrnount of a
rzrdiolabeled drug targeting conqtruct in actilated endothelial cells u'ill hrrdlv exceecl the
levels of racliolabeled constructs in the blood in the particular organ. In addition, it is
difficult to distinguish selectively bound radioactivitl from accurrulated radioactir-irv due tc.r
enhanced permeabiLitr, at the site of inflammation (unpublished obsenations). As a solution
to these problen-rs, the use of a clual labeling techni<1ue can be recon-rmended, rvhere
accumulation of a 12sl-labeled binding construct is comparcd to a simultaneously
administered r31I-labeled non-binding control construct [ 1]. Hou'evcr, extrapolation of the
accordingly determined accunrulaterl amount to therapeutic effects is not possible without
knowledge of in uiuo pharmacokinetic-pharmacodvnamic relationships of developed drug
targeting constrlrcts. Until the se re lationships are cladficd, direct dctermination of
pharmacoiogical effects of new-ll developed drug targeun5i preparations will therefore
remain of prime importance to determine the therapeutic slrccess of the drug targeting
stfategl"
It must be realized that the added therapeutic value of targetinq drugs to activated
endothelial cells still needs to be determined. It has not been established yet, rvhether
cl'rronic inflammation u.ill be resolved bv inhibiting endothelial cell activation. This que stion
can be addressed with the der.'elopment of potent drug trrrgeting colrstructs and availabiLin'
of proper re xd-our parame ters. Now-adays, RT-PCR is rr iclcl]' used to studl
pharmacological effects of drugs on the expression of susceptible llefles. Because
endothelial cells constirute onlv a small number of the total ceil population in a particular
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stud1. the effects of the delivered clrug at the endotheiial cell level using RT PCR. This
isolation can be performed using aclvanced techniques such as laser dissection microscopr'.
Gene cxpression arrav analr,sis can also be applied to determine which genes in endothelial
celis are up- or downrcgulated b,v the delivered drug. However, because the yield of isolated
mRNA u'i1i be relativelv lorv using laset dissection microscopv, linear amplification of
mRNA will bc obLigatory to detect transcriptional levels of less abundant gcne transcripts.
r\lternativelv, in situ hybridisation mar. be considered as a useful technique to determine
pharmacological effects ofl gene expression. Using this procedure endothelial cells can be
visually icientifiecl because the morpholog'r' of the tissue under stud,v is retained. However,
this techniclue has less amplification power compared ro RT-P(iR, rvhich mav implicitlr-
lead to less sensitivity of the determination of eventual pharmacological effccts.
After detcrmination of pharmacological effects at the endothelial cell level, clinical
parameters such as joint su,-elling in the case of rheumatoid arthritis need to be estabLished
to dcterminc thc therapcutic impact of the strategr,.
The cleveloped Ir-selectin clirected drug targeting constructs described in this thesis have
not been investigated \ret regardiflll their therapeutic applications; onlv pharmacological
effects oi the dexa Ab1q..1 conjugates ha'n'e been demonstateLT in uilru. Further research is
recluirecl to determine the potential of the developed drug targeting preparatlons to exert
anti-inflammatorr. effects in uiuo, a.lso during chronic administrarion. Lastlv, it should be
kept in mind that targeting drugs to activated endotheliai cells mav prove to be an
important pharmacobgical tool to clarify the role of the endothe[um in pathophl'siologrcal
processes in inflammation. This knowlcdge will eventuallv contribute to the development
of novel therapies for chronic inflammaton' diseases.
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